Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Core Points - Soligenix, Inc. announced the adjournment of its 2024 Annual Meeting of Stockholders to solicit additional votes on proposals outlined in its definitive proxy statement [1][5] - The reconvened Annual Meeting is scheduled for May 30, 2024, at 9:00 a.m. Eastern Time, and will be held virtually [2] - As of the adjournment, approximately 48% of the shares of common stock had been voted, which was below the required quorum [3] Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs [7] - The company is advancing HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma, and is seeking regulatory approvals following the successful completion of its second Phase 3 study [7] - Other development programs include SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases, and SGX945 for Behçet's Disease [8] Public Health Solutions - The Public Health Solutions segment includes the development of RiVax®, a ricin toxin vaccine candidate, and vaccines targeting filoviruses and COVID-19 [9] - These programs are supported by government funding from agencies such as NIAID, DTRA, and BARDA [9]